Treeline Biosciences Commences Phase 1 Trials and Secures $200 Million Series A Extension Funding

Treeline Biosciences initiates Phase 1 trials for three new programs and raises $200 million in Series A extension funding.

AI-assisted, human-published

Latest headlines

Join us for funding and investment opportunities.

Stay connected!

If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here